Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elicio Therapeutics Inc (NQ: ELTX )

5.120 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Elicio Therapeutics Inc

< Previous 1 2 Next >
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Proposed Public Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma 
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
From Elicio Therapeutics Inc.
Via GlobeNewswire
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.